SBI Securities’s Ensysce Biosciences ENSC Stock Holding History

SBI Securities’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$261	Sell	627 -14	-2%	-$5	﹤0.01%	3327
2026 Q2	$186	Buy	641 +155	+32%	+$56	﹤0.01%	3349
2026 Q1	$262	Buy	486 +65	+15%	+$41	﹤0.01%	3121
2025 Q4	$387	Buy	421 +3	+0.7%	+$6	﹤0.01%	2968
2025 Q3	$991	Sell	418 -1,918	-82%	-$4.12K	﹤0.01%	2695
2025 Q2	$5.21K	Buy	+2,336	New	+$5.35K	﹤0.01%	1970

Other funds holding ENSC

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Golden State Equity Partners South Coast Metro, California $1.7B AUM 14.02% 1-Year Est. Return

SBI Securities's ENSC Position: Q3 2026 in Review

SBI Securities reduced its Ensysce Biosciences (ENSC) stake by 2.2% in Q3 2026, selling an estimated $5 and leaving 627 shares worth $261. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

SBI Securities first reported a position in ENSC in Q2 2025 and has held it in 6 quarters since. The position peaked at $5.21K in Q2 2025. 6 funds tracked by Wall St. Rank hold ENSC as of Q3 2026.

SBI Securities held 627 shares of Ensysce Biosciences worth $261 as of Q3 2026.
SBI Securities sold 14 Ensysce Biosciences shares in Q3 2026, an estimated $5.
Ensysce Biosciences made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3327 holding.
SBI Securities first reported a position in Ensysce Biosciences in Q2 2025 and has held it in 6 quarters since.
SBI Securities's Ensysce Biosciences position peaked at $5.21K in Q2 2025.
6 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.